Giuseppe
Emeritus
Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children (Euro Surveill., letter, extract, edited)
[Source: Eurosurveillance, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19679">Eurosurveillance - View Article</cite>. 1st two paragraphs, edited.]
Eurosurveillance, Volume 15, Issue 40, 07 October 2010
Letters
Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children
R Lopert 1
1. Therapeutic Goods Administration, Australia
Citation style for this article: Lopert R. Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children. Euro Surveill. 2010;15(40)
ii=19679. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19679
Date of submission: 28 September 2010
To the editor:
In a recent issue of Eurosurveillance, Kelly et al. conclude that the risks associated with the 2010 trivalent influenza vaccine from CSL Biotherapies outweighed its benefits, based on a comparison of the risk of hospitalisation due to influenza compared with that arising from an adverse reaction [1]. However the analysis is misleading and the authors? conclusions must be considered unsound.
The authors fail to recognise the obvious and significant differences between being hospitalised for overnight observation following a febrile convulsion and being admitted to intensive care units in respiratory failure as a result of influenza infection. A study in the United States conducted in 2006 reported a 15% intensive care units admission rate in children in this age group hospitalised with influenza infection [2].
(...)
-
------
[Source: Eurosurveillance, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19679">Eurosurveillance - View Article</cite>. 1st two paragraphs, edited.]
Eurosurveillance, Volume 15, Issue 40, 07 October 2010
Letters
Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children
R Lopert 1
1. Therapeutic Goods Administration, Australia
Citation style for this article: Lopert R. Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children. Euro Surveill. 2010;15(40)
ii=19679. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19679Date of submission: 28 September 2010
To the editor:
In a recent issue of Eurosurveillance, Kelly et al. conclude that the risks associated with the 2010 trivalent influenza vaccine from CSL Biotherapies outweighed its benefits, based on a comparison of the risk of hospitalisation due to influenza compared with that arising from an adverse reaction [1]. However the analysis is misleading and the authors? conclusions must be considered unsound.
The authors fail to recognise the obvious and significant differences between being hospitalised for overnight observation following a febrile convulsion and being admitted to intensive care units in respiratory failure as a result of influenza infection. A study in the United States conducted in 2006 reported a 15% intensive care units admission rate in children in this age group hospitalised with influenza infection [2].
(...)
-
------